Dyslipidemia
Authors: Christine Laine
Journal: Annals of Internal Medicine (2007)

In the Clinic4 September 2007DyslipidemiaChristine Laine, MD, MPH, David R. Goldman, MD, Laurie Kopin, MS, ANP, and Thomas Pearson, MD, PhDChristine Laine, MD, MPHSearch for more papers by this author, David R. Goldman, MDSearch for more papers by this author, Laurie Kopin, MS, ANPSearch for more papers by this author, and Thomas Pearson, MD, PhDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-147-5-200709040-01009 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Editor's Note: This issue of In the Clinic has been updated.Dyslipidemia affects 1 of every 2 American adults and is a major risk factor for cardiovascular disease (CVD), cardiovascular death, and all-cause mortality. Large observational studies have found a strong, graded relationship between increasing levels of low-density lipoprotein (LDL) cholesterol or decreasing levels of high-density lipoprotein (HDL) cholesterol and increasing risk for coronary artery disease (CAD) events (1, 2). Long-term prospective epidemiologic studies have consistently shown that persons with healthier lifestyles and fewer coronary risk factors, particularly those with normal lipid profiles, have an overall lower incidence of CVD. ...References1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA. 1987;257:2176-80. [PMID: 3560398] Google Scholar2. Goldbourt U, Yaari S. Cholesterol and coronary heart disease mortality. A 23-year follow-up study of 9902 men in Israel. Arteriosclerosis. 1990;10:512-9. [PMID: 2369362] Google Scholar3. Grundy SM, Balady GJ, Criqui MH, et al. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation. 1997;95:2329-31. [PMID: 9142014] Google Scholar4. National Cholesterol Education Program. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Institutes of Health: Bethesda, MD 2002. NIH No. 02-5215 accessed at www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf on 11 July 2007. Google Scholar5. Screening for Lipid Disorders in Adults. U.S. Preventive Services Task Force: Rockville, MD; 2001. Accessed at www.ahrq.gov/clinic/uspstf/uspschol.htm on 11 July 2007. Google Scholar6. Cleeman JI, Grundy SM. National Cholesterol Education Program recommendations for cholesterol testing in young adults. A science-based approach. Circulation. 1997;95:1646-50. [PMID: 9118536] Google Scholar7. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-6. [PMID: 10612322] Google Scholar8. Murray DM, Kurth C, Mullis R, et al. Cholesterol reduction through low-intensity interventions: results from the Minnesota Heart Health Program. Prev Med. 1990;19:181-9. [PMID: 259741] Google Scholar9. Craig SR, Amin RV, Russell DW, Paradise NF. Blood cholesterol screening influence of fasting state on cholesterol results and management decisions. J Gen Intern Med. 2000;15:395-9. [PMID: 10886474] Google Scholar10. Cooper GR, Myers GL, Smith SJ, et al. Blood lipid measurements. Variations and practical utility. JAMA. 1992;267:1652-60. [PMID: 1542176] Google Scholar11. Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA. 1995;274:801-6. [PMID: 7650803] Google Scholar12. National Cholesterol Education Program. Risk Assessment Tool for Estimating 10-year Risk of Developing Hard CHD (Myocardial Infarction and Coronary Death). National Institutes of Health: Bethesda, MD; 2002 Accessed at http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof on 11 July 2007. Google Scholar13. Brand FN, Larson M, Friedman LM, et al. Epidemiologic assessment of angina before and after myocardial infarction: The Framingham study. Am Heart J. 1996;132:174-8. [PMID: 8701860] Google Scholar14. Grundy SM. Statin trials and goals of cholesterol-lowering therapy [Editorial]. Circulation. 1998;97:1436-9. [PMID: 9576422] Google Scholar15. Miller M. Is hypertriglyceridaemia an independent risk factor for coronary heart disease? The epidemiological evidence. Eur Heart J. 1998;19 Suppl H:H18-22. [PMID: 9717060] Google Scholar16. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450-8. [PMID: 17190864] Google Scholar17. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B-12B. [PMID: 9526807] Google Scholar18. Ernst ND, Sempos CT, Briefel RR, et al. Consistency between US dietary fat intake and serum total cholesterol concentrations: the National Health and Nutrition Examination Surveys. Am J Clin Nutr. 1997;66:965S-972S. [PMID: 9322575] Google Scholar19. de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99:779-85. [PMID: 9989963] Google Scholar20. Carleton RA, Bazzarre T, Drake J, et al. Report of the Expert Panel on Awareness and Behavior Change to the Board of Directors, American Heart Association. Circulation. 1996;93:1768-72. [PMID: 8653885] Google Scholar21. Grundy SM, Pasternak R, Greenland P, et al. V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100:1481-92. [PMID: 10500053] Google Scholar22. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-7. [PMID: 7566020] Google Scholar23. West of Scotland Coronary Prevention Study Group. The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men. J Am Coll Cardiol. 1999;33:909-15. [PMID: 10091815] Google Scholar24. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 998;279:1615-22. [PMID: 9613910] Google Scholar25. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.Lancet.1994;344:1383-9. [PMID: 7968073] Google Scholar26. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med. 1998;129:681-9. [PMID: 9841599] Google Scholar27. The Long-Term Intervention with Pravastatin in Ischaemic Disease Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 998;339:1349-57. [PMID: 9841303] Google Scholar28. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409-15. [PMID: 12719279] Google Scholar29. Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1084-91. [PMID: 12423708] Google Scholar30. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005;80:587-95. [PMID: 15887425] Google Scholar31. American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140:650-8. [PMID: 15096337] Google Scholar32. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004;140:644-9. [PMID: 15096336] Google Scholar33. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788-97. [PMID: 17159064] Google Scholar34. Miettinen TA, Puska P, Gylling H, et al. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med. 1995;333:1308-12. [PMID: 7566021] Google Scholar35. Jenkins DJ, Kendall CW, Vidgen E, et al. Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am J Clin Nutr. 1999;69:395-402. [PMID: 10075322] Google Scholar36. Stevinson C, Pittler MH, Ernst E. Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med. 2000;133:420-9. [PMID: 10975959] Google Scholar37. American College of Physicians. Medicare Pay-for-Reporting Program: Physicians Quality Reporting Initiative (PQRI) Resources Physicians Quality Report Initiative (PQRI) Overview. Accessed at www.acponline.org/pmc/pqri.htm on 11 July 2007. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCorrection: In the Clinic: Dyslipidemia Metrics Cited byFenofibrate-associated nephrotoxicity: A review of current evidence 4 September 2007Volume 147, Issue 5Page: ITC9-1KeywordsCardiovascular diseasesCholesterolDrug therapyDrugsDyslipidemiaLipidsMedical risk factorsStatins ePublished: 4 September 2007 Issue Published: 4 September 2007 Copyright & PermissionsCopyright © 2007 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...